Thomas Hanke

Thomas Hanke, PhD is a Board Member at Tubulis.

Thomas is an industry expert with more than 30 years of experience in research and drug discovery. He serves as Executive Vice President and Head of Academic Partnerships at Evotec, where he is responsible for growing and guiding a portfolio of strategic academic partnerships, pre-seed incubators and investments into spin-out companies. Prior, he oversaw Evotec’s drug discovery portfolio in inflammation and immuno-oncology, generating and building on high-value, performance-based alliances with academia and pharma. Thomas currently serves on the Board of OXVax, Dark Blue Therapeutics and Autobahn Labs. Before Evotec, Thomas was Sourcing Director at the Biopharmaceuticals Research Unit of Novo Nordisk. He was also a co-founder and Chief Scientific Officer of TeGenero, heading the company’s R&D efforts to develop first-in-class immunomodulatory monoclonal antibodies.

Thomas holds a PhD in Biology from the University of Würzburg, where he also served as a group leader and Assistant Professor for Immunobiology.